lymes vaccine compications and how I can find help

Posted Answers


Look into EDTA Chelation.

Lyme Disease - Topic of New Book
I am a member of the Chelation Discussion Group, headed by the guru of Chelation therapy, Garry Gordon, M.D., D.O. It may have well over 200 health professional members now on a worldwide basis. The theme seems to be primarily questions answered by Dr. Gordon as well as astute contributions from the members. Well, there is a tremendous number of communications per week. I used to print them all out and save them, but now I have decided to record the essence of many of the teachings in my brain.

During a recent letter, a man was diagnosed with Parkinson's disease and was not improving with the conventional drug therapy. He was found to have underlying Lyme disease. He was treated with a special type of the herbal Cat's Claw or Una de Gato by the name of SAMENTO. It is by Nutramedix and comes in 120 mg and 600 mg capsules. My supplier is Emerson Ecologics in NH. They deal directly with health practitioners and not lay people.

I must say that the flow of the article is a bit confusing to me but I think I got the big picture. I am focusing on the excerpt about the "Lyme Connection." Many years ago I remember riding along a CT highway and photographing the LYME sign -- trivia but was thinking of the disease.

A study was done on twenty-eight Lyme disease patients -- all diagnosed by the Western Blot blood test. The fourteen patients in the control group were treated with conventional antibiotics. Three slightly improved; three got worse and the rest had no change. In the experimental group of fourteen patients treated with Pentacyclic Alkaloid Chemotype Uncaria tomentosa, 85% tested negative for Lyme disease and all of the patients experienced a dramatic improvement in their clinical condition.

This substance Pentacyclic Alkaloid chemotype Uncaria tomentosa is also known as TOA-Free Cat's Claw. The TOA stands for tetracyclic oxindole alkaloids that is not present in the Cat's Claw used in the study. TOA is a group of chemical antagonists that act upon the central nervous system and greatly inhibit positive effects of pentacyclic oxindole alkaloids.

In conclusion, I wish to alert both the health professionals and the lay people of the importance to check for Lyme disease in patients with Parkinson's disease and with ALS or Lou Gerhigs' Disease. (Might be smart to do for patients with other neurological illnesses!) If this Western Blot test is positive for Borrelia burgdorferi, the bacteria that causes Lyme disease, strongly consider treating the patient for Lyme disease with this special type of Cat's Claw.

I feel that this is a most important message and hope you will consider sharing it with others and thus helping others.


PLANETNEWS broadcast...

Plum Island is a small island off the coast of Long Island, NY. The author was interviewed this morning on the Today Show.

William Morrow, A biological time bomb?

New book tells the story of the U.S. government's secret Plum Island germ laboratory and claims it's a ticking biological time bomb none of us can safely ignore. Read an excerpt of Michael Carroll's new book.

Updated: 4:59 p.m. ET Feb. 19, 2004

It sounds like the script from a science fiction movie dozens of deadly and rare biological diseases, housed on a bucolic island just a stone's throw from some of the wealthiest homes in America, with a history of contagious outbreaks, poor security, official denials, and perhaps most frightening of all, a potential terrorist target.

Unfortunately, it's not science fiction. According to "Lab 257," a new book by Michael Carroll, it's exactly what's going on just hours from New York City at the Plum Island Animal Disease Center in Long Island, New York. Carroll discusses the book on Today. Read an excerpt here: 1975: The Lyme Connection


Have you ever heard of Lyme disease? I am writing this letter because I know you can help thousands of people by warning them about this awful sickness. I have been battling it for 18 months. Frankly I am not doing well.

It would be impossible for me to describe the emotional and physical pain that I have been through. I am a 42-year-old man, married nearly 20 years, and have a family. The days of slinging a 100-pound sack of birdseed over my shoulder and walking to the backyard are over.

Today I can't even lift a five-pound sack of flour. There was a time when I could play nine musical instruments. I sang in the church choir and ran my own small business. Today, I do none of the above.

I am saving all my energy to fight Lyme disease.

The treatment costs are staggering. IV antibiotic therapy runs from $150 to $475 a treatment ... We have already taken out a third mortgage on our home. Had I been aware of the symptoms from the beginning, I could have had $15 worth of oral antibiotics and that would have done the job.

Thank you, for allowing me to try to help others.


Protecting a nuclear power plant is no small task. When it opened in the 1980s, the Shoreham nuclear power plant on Long Island's North Shore boasted a 175-man militia equipped with Uzi 9-millimeters, AR-15 assault rifles, and 12-gauge shotguns. This elite paramilitary unit patrolled the "protected area," a dense forest hundreds of acres deep that buffered the "controlled area," a huge concrete dome sheltering the uranium nuclear reactor. Every eight hours, a fresh detachment of fifty men, armed to the teeth and clad in steel-toed boots, tan pants, and khaki shirts, marched in lockstep through the protected area along dirt paths and through marshes, their watchful eyes and ears continually scanning for intruders. One Shoreham security officer, a short, blond-bearded, barrel-chested man, remembers the scene during the 3:00 P.M. to 11:00 P.M. shift in October 1987. His platoon had just moved out, marching into a field where they often spotted herds of thirty or forty wild deer darting ahead of them into the wooded glen. He felt a brief pinch on his left ankle and thought it was the stiff new Army boots he was breaking in. Later that night, he went home and showered. Pulling off his white tube socks, he noticed a small red mark on his ankle. Those damn boots he thought, and went to bed.

When he awoke the next morning, the nagging blister had grown, so he grabbed tweezers from the bathroom vanity and poked at the area. Suddenly, something started to move, and he realized it wasn't a
blister at all. It was a live bug. Panicked, he frantically dug into it. As he extracted the critter, it broke in two, spilling its insides into the microscopic holes it punched into his body.

Seventy-two hours later, he thought he had caught the flu. Within a week, his joints began to ache.

Most people don't think of deer as swimmers. But swim they do. Indigenous to most of the United States and Canada, white-tailed
deer can swim distances as long as four miles.

Their natural predators wolf, bear, mountain lion, and coyote are long extinct from the northeastern landscape, but one tiny foe remains. Poised atop a blade of grass, the deer tick waits patiently for anything warm-blooded to brush by, feeding on deer as well as smaller creatures like birds and mice. The tick jumps aboard and pierces its sharp mouth hooks into the skin of its unlucky host. A tiny glutton with a king-sized appetite, the tick sucks the blood of its host in a feast that can last up to two whole days, while it swells to a bubble over three times its original size. At the same time, the little parasite deposits its own fluids into the host, fluids that sometimes prove fatal.

The feeding habits of ticks and the swimming abilities of deer were of little concern to the residents of Old Lyme, Connecticut, in July 1975. This quaint New England town is, for the most part, an upper-crust community with tree-lined streets and fine colonial and Federal-style homes. As one of America's oldest towns, founded by English Puritans, Old Lyme was enjoying its tricentennial as the nation prepared for a bicentennial. But a strange set of occurrences that year would forever change its reputation from a warm charming enclave to a place of fear and despair.

Old Lyme, nestled on the banks of the Connecticut River, sits just a shade north of the Long Island Sound. The midsummer weather in 1975 was typical for coastal Connecticut hot, sticky, and humid. As little ones frolicked in the sun, ignoring the blistering heat, and grown-ups sought refuge on their porches by night, grateful for a balmy summer breeze, Polly Murray and Judith Mensch noticed something unusual about their children. Seemingly out of nowhere, they were showing signs of strange physical and mental ailments. Alarmed, the two mothers quickly phoned their neighbors, who were observing strikingly similar conditions in their own children. Many of the kids in the neighborhood and some adults were suffering from the same skin rashes, throbbing headaches, and painful swollen joints.

Together, Polly and Judith brought their concerns to the Connecticut Department of Health, which immediately appointed physicians from Yale University to investigate. Initially, the doctors misdiagnosed thirty-nine children and twelve adults with juvenile rheumatoid arthritis, a condition they named "Lyme arthritis," after the town where the strange outbreak occurred. Two years later, scientists linked Lyme arthritis to the bite of a deer tick. And in 1981, Dr. Wally Burgdorfer, a researcher at the National Institutes of Health, discovered thin spiral bacteria in technical terms a spirochete immersed in the fluid of a deer tick. He proved that the new spirochete was to blame not for Lyme arthritis, but for an entirely new ailment: Lyme disease.

The foregoing is excerpted from "Lab 257" by Michael C. Carroll. All rights reserved. No part of this book may be used or reproduced without written permission from HarperCollins Publishers, 10 East 53rd Street, New York, NY 10022. To learn more you can visit:


Dear Doctors:
Dr. Kupsinel is a long time friend and wants everyone to stay abreast of the unfolding story of Lyme disease. Dr. Kupsinel's contribution to your education on LYME, which is INCREASING seen as a contributor to many SERIOUS health problems, is generally being seriously under diagnosed. But after all, that applies to all of these chronic, difficult to treat infections, including the infections found in EVERYONE with Alzheimer's, and Parkinson's, and Cancer and in the Vulnerable Plaque that leads to the fatal blood clot that KILLS 1.9 million patients in the US alone each year.

Of course, I differ with everything that anyone says about it because I simply choose to forget about WHICH infection we have and assume that everybody carries a serious underlying unhealthy total body pathogen burden. This can go under many names from cell wall deficient organisms to Pfeisteria, to SV-40 and all the usual mycoplasma infections, Candida, fungal, viral etc. that we all know most of us if adequately evaluated will test positive for one or more of these problems, usually many of them. We also know that most efforts to eradicate will in the long run fail. Well documented in, for instance, Chlamydia even 1 year of antibiotics never fully eradicates and when the antibiotics are discontinued the original infection returns. Proven that overuse of antibiotics doubles BREAST CANCER rates, we know that we have probably also HARMED the patient with the associated degradation of bowel flora.

I happen to subscribe to the school of OXIDATIVE THERAPIES and love HIGH DOSES OF VITAMIN C, ORAL AND IV, along with massive doses of IMMUNI-T 2 and 3, KYOLIC (garlic) and biological response modification with the ONLY active form of CAT'S CLAW That really works, SAMENTO. If you think the infection could be INTRACELLULAR as Malaria, always remember to add Artemisinin, which is famous around the world for its proven ability to handle malaria when all drugs are failing.

If you somehow are not getting the results you need with vitamin C, we believe this means that the serum levels are not getting high enough to handle the infection. Remember that Beyond C is provably maintaining far higher levels for far longer than ANY form of Vitamin C ever tested.

However, if this approach is simply not handling the problem adequately, then I have found that you can add Ozone and/or Ultraviolet blood irradiation and/or H202 as the next step. Ozone can be VERY helpful even without IV application. It can be given rectally and through the external auditory canals (using a stethoscope to administer the material) and even as a steam sauna or given as a body bag approach.

This topic of various OZONE applications will be covered in depth in a special workshop, when attendees at my April 17-18 Phoenix conference will learn how to register to attend sometime this summer, and become PROFICIENT in administering OZONE by many different routes.

Garry F. Gordon, MD,DO,MD(H)


Moderator's Note: No one needs to save any of these emails, as YAHOO does this for us. Every email since the group started in April 2001 is SEARCHABLE by topic or message number when you are logged into YAHOO and on our discussion group site. Think of it as your personal FILE cabinet and if you don't have a "key", contact for directions on how to access it.


For complex medical questions, we advise that you make an appointment for a personal, recorded, telephonic consultation with me. Each consultation is recorded and provided to you on audio CD. To schedule an appointment, call (928) 472-4263, Monday through Friday, during standard business hours.

Garry F Gordon MD DO MD(H)
Gordon Research Institute
600 N Beeline Hwy, Suite B, Payson, AZ 85541
Ph: (928) 472-4263 Fax: (928) 474-3819
All contents © 2004 GRI. All rights reserved.

 Answer by email


Is the Lyme Disease Vaccine a Lemon?

WebMD Health NewsReviewed by Craig H. Kliger, MDJan. 31, 2001 (Washington) -- Could a vaccine be more dangerous than the disease it's supposed to prevent? That question was heavy in the air Wednesday, as the Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee held a special session on the safety of Glaxo SmithKline's Lyme disease vaccine LYMErix.

The panel held the meeting to review reports that indicate the vaccine may somehow trigger treatment-resistant Lyme arthritis and other chronic arthritic disorders.

About two-and-a-half years ago, the same committee had recommended that the FDA approve the vaccine, and panel members said they were frustrated that additional studies have failed to clear up uncertainties about adverse events that may be linked to the vaccine.

In the end, most panel members said they supported revisions and possible new warnings on the vaccine's package inserts, as well as heightened public education about the potential risks of the vaccine.

Lyme disease most commonly affects individuals in New England and the mid-Atlantic states. It's transferred to humans via deer ticks that live in grassy and wooded areas, with May and June being the highest-risk months for transmission. The disease was first recognized in 1975, and the vaccine maker says that it is still on the rise. More than 100,000 cases were reported to the federal government between 1982 and 1998.

Lyme disease isn't life threatening, but its long-term effects can include joints destruction, neurological disorders, and other serious conditions.

The LYMErix vaccine was approved late in 1998 for use in those at least 15 years old. It's been marketed in the U.S. since January 1999, and Glaxo SmithKline says that it has distributed 1.4 million doses, although it acknowledged that fewer patients than expected have actually received the vaccine.

The vaccine series, which is administered in three separate doses, is relatively costly. Each dose costs about $50. Despite the cost, its effectiveness is somewhere less than 80%.

Even as panel members noted that science on the vaccine's safety has not advanced in recent years, they said that anecdotal complaints from patients have increased dramatically. A series of Lyme vaccine recipients and patient advocates made often-emotional presentations to the panel, urging that the vaccine be pulled from the market, that it be put on hold until ongoing safety studies are completed, or that stronger warnings go on the product's labeling.

But a series of researchers from Glaxo SmithKline maintained that the vaccine was unrelated to arthritis or other mysterious conditions, and outlined a set of studies that it has under way. The company says that the product's safety profile hasn't changed since it was approved.

The patients' testimonials clearly had an effect on the advisory committee. In his closing remarks, W. Michael O'Fallon, PhD, an invited participant in the panel's discussion, said, "Would I take the vaccine? No."

Is the Lyme Disease Vaccine a Lemon?

Benjamin Luft, MD, another invited participant, cited a "twilight zone" of disconnect in the conflicting accounts of the vaccine recipients and the drug firm.

According to panel member David Stephens, MD, a "huge body of anecdotal data" suggests that "we may be missing something."

Almost 1,000 adverse event reports have been filed on the Lyme vaccine, with around 70 citing arthritis-like side effects. Four deaths also have been reported following administration of the vaccine.

But according to Glaxo SmithKline, the events have taken no particular clinical pattern and "no cluster in time to onset."

According to the FDA, the rates of arthritis suffered by those who've taken the vaccine aren't higher than rates among the general population.

The FDA holds that more adverse events are occurring than are reported, but agrees with the vaccine maker that most of the reported events involve side effects already described in the vaccine's physician labeling.

The company says it has experience with more than 18,000 subjects in controlled investigations, including more than 8,000 post-licensure vaccinees.

Glaxo SmithKline presented animal study data that it claimed supported its position that the vaccine is unrelated to the arthritis. But panel member Steve Kohl, MD, and others said the study was irrelevant to the nature of the possible problem in humans.

The drugmaker also said that it was tracking actual vaccinations as delivered by physicians through three HMOs, so it can closely follow thousands of doses, possible side effects, and follow-up medical care. By the end of the year, said Glaxo researcher Richard Platt, MD, "We will have real information about the relative risks."

But several members of the panel said that they were worried that the study would not be large enough to provide definitive data on the supposed connection between the vaccine and arthritis.

The panel did not hold any formal votes and is not responsible for deciding FDA policy.

 Answer by email


Did Lyme Vaccine Give
People The Disease & Arthritis?

Concerns Grow Over Reactions to Lyme Shots

By Holcomb B. Noble
NY Times

Federal health authorities are investigating whether some people who received the vaccine against Lyme disease later developed severe cases of arthritis and even Lyme disease itself as a result.

The Food and Drug Administration has received reports of such problems, mainly from doctors and researchers in the Northeast. The vaccine, made by SmithKline Beecham Biologicals, a subsidiary of the British pharmaceutical giant SmithKline Beecham, was approved by the drug agency two years ago, and about 440,000 Americans have received it. SmithKline Beecham defends it as safe.

Dr. Susan S. Ellenberg, director of biostatistics and epidemiology at the F.D.A., said the agency, working with the Centers for Disease Control and Prevention, would investigate the reports "to find out what the cases really are, to get more information." Dr. Ellenberg and Dr. Walter A. Orenstein, assistant surgeon general and director of the centers' national immunization program, said it remained to be determined whether the vaccine was the cause of the reported illnesses.

"We have a vaccine that provides considerable, proven benefit , about 80 percent protection against Lyme disease and only theoretical risk with respect to arthritis," Dr. Orenstein said.

As a first step, the investigators will seek to determine whether, over all, vaccine recipients report arthritis or Lyme disease more often than people who have not received the vaccine. Until that initial step is taken, there is no evidence that the vaccine causes problems.

There is no way to determine how many people believe they have developed health problems caused by the vaccine. But in interviews, more than a dozen doctors in areas where Lyme disease is common say they have treated 170 people with arthritis and Lyme disease that they attribute to the vaccine.

According to SmithKline Beecham, the vaccine was tested in controlled, double-blind clinical trials involving 10,936 people; after two years, those who were vaccinated were not reported to have suffered any more illnesses than those who were not.

But when the drug agency's vaccine advisory committee recommended that the vaccine be approved for marketing, several members expressed concern that the vaccine could set off an autoimmune condition that, in turn, would result in arthritis. Some also said they feared it could cause flare-ups of Lyme disease among people previously infected with the Lyme bacteria, Borrelia bergdorferi.

Ultimately, in May 1998, the advisory committee endorsed the vaccine unanimously, concluding that the concerns were only theoretical and that data gathered in the clinical trials showed that the vaccine was safe. Carmel Hogan, a spokeswoman for the company, said of the vaccine: "Lymerix is the only clinically proven vaccine to protect against Lyme disease and both the F.D.A. advisory committee and the F.D.A. Office of Vaccines have determined that the vaccine is safe."

Until now, the government was actively investigating illnesses that broke out after vaccination only if they were officially classified as serious ,Äî defined as life-threatening, persistent and long-term or requiring hospitalization. Lyme disease and arthritis were not generally regarded as meeting those criteria.

Researchers from both the drug agency and the disease-control centers will now investigate all cases of arthritis and all symptoms of Lyme disease reported to have developed after a patient has been vaccinated, Dr. Ellenberg said. The cases under investigation are concentrated in seven states: Delaware, New Jersey, Pennsylvania, Connecticut, New York, Massachusetts and Wisconsin.

Dr. Orenstein likened the new investigations to those begun in the fall of 1998 after the licensing of the rotavirus vaccine against childhood gastroenteritis. Within six months, doctors reported 15 cases of intestinal blockages among vaccinated infants; though the number of cases was small, the rate was so much higher than normal that the drug and disease-control agencies declared a moratorium on the vaccine's use while the investigation continued. In October 1999, 98 cases cases had been reported and the manufacturer, American Home Products of Madison, N.J., withdrew the vaccine from the market, Dr. Orenstein said.

Some doctors say the drug agency should never have approved the Lyme vaccine or should have responded more quickly to adverse reports. Dr. Andrea Gaito, a New Jersey rheumatologist and president of the International Lyme and Associated Disorders Society, said she had told the agency that 21 patients developed severe arthritis soon after being given the vaccine by other doctors.

Dr. Gaito, who does not give the vaccine, said she believed that the vaccine caused arthritis and Lyme disease itself but that the problems were not always linked to it because the vaccine took effect only after three immunization shots given over the course of a year. "The F.D.A. had just better withdraw this vaccine now," Dr. Gaito said.

Dr. Charlene C. Demarco of Egg Harbor, N.J., an internist and family doctor, said 50 of her patients had developed autoimmune arthritis after receiving Lyme vaccine from other doctors and 30 others appeared to have flare-ups of previous Lyme infections.

Dr. Demarco said the agency had not moved quickly enough after initial reports of adverse effects.

Dr. Ellenberg conceded that the drug agency had at times acted too slowly. "We wish that some of these cases had been brought to our attention sooner," she said. "They should have been given a higher priority." She said "we have made that clear" to the unit that takes in the reports and records the medical data.

Still, other doctors and clinicians challenged the suggestion that the 170 people who developed problems suffered them because of the vaccine. "I would say, `Show me the data,' " said Dr. Gregory A. Poland, chief of vaccine research at the Mayo Clinic in Rochester, Minn.

Even though the vaccine advisory committee recommended approval of Lymerix, the panel's chairwoman, Dr. Patricia L. Ferrieri of the University of Minnesota Medical School, said it had taken the action with unusual "ambivalence" because of concerns about the possibility of severe reactions.

Dr. Allen C. Steere, who directed SmithKline Beecham's trials of the vaccine, told the committee that it was hypothetically possible that the vaccine could set off an autoimmune reaction in which the body's immune system attacks its own tissue, and that this could cause treatment-resistant arthritis.

Dr. Steere had expressed the concern as early as 1995, shortly after the start of the clinical trials, when he said that some patients were already developing joint pain after getting the vaccine.

"A small percentage of patients have developed joint pain and arthritis following vaccination," Dr. Steere said in a letter to the National Institutes of Health.

As far back as 1989, Dr. Steere and research colleagues found that people with what they called prolonged, treatment-resistant Lyme arthritis often carried a gene variant called HLA-DR4. The suspicion was that among those people, some chemical component in their joint tissue resembled a chemical in the invading Borrelia bergdorferi. This, it was thought, could cause the immune system to attack a person's own tissue along with the foreign bacteria.

In July 1998, two months after Dr. Steere recommended the vaccine's approval, he and colleagues reported in the journal Science that they believed they had found the guilty molecular twins: a piece of protein on the outer surface of the Lyme bacteria was strikingly similar, they said, to a natural human protein in blood and other cells. This raised the theoretical possibility that when an infected tick bites a human, the person's immune system T-cells, the soldiers on the front line of the body's defense against disease, could destroy not only the foreign invader but also some of the body's own protein.

Some 60 patients who believe they were made ill by the Lyme vaccine are suing SmithKline Beecham for monetary damages, said Stephen A. Sheller, a lawyer with Sheller, Ludwig & Badey, of Philadelphia, which is handling the suits. And class-action suits have been filed by the firm in New York, New Jersey and Pennsylvania seeking to require the company to warn doctors and patients that it poses possible risks for those who are genetically predisposed to autoimmune arthritis or who have been previously infected with Lyme bacteria.

 Answer by email

Share this with your friends